BUZZ-Haemonetics rises after BofA upgrades to "neutral" on prudent growth forecast** Medical device maker Haemonetics's shares HAE.N rise 4% to $69.79
** BofA Global Research ups to "neutral" from "underperform" and raises PO from $58 to $75, 11.4% above last close
** BofA sees setup as less risky since HAE's "prudent" forecast does not depend on rebound in vascular‑closure device Vascade, and also left upside in plasma volume
** Notes HAE lowered Vascade recovery expectations, meaning a sharp rebound isn't needed just to meet guidance
** Sees upside in plasma volume growth, which returned to high single digits in the US and double digits in Europe last qtr
** Including session's move, HAE stock down ~10% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.